Answers are grounded in this paper and cite their sources.
Cell-free DNA (cfDNA) is expected to contribute to the decision for treatment and prediction of effects with minimally invasion. We investigated the correlation between gene mutations before and after lenvatinib (LEN) treatment and its effectiveness, in order to find advanced hepatocellular carcinoma (HCC) patients who would benefit greatly from the therapy.
No takes yet. Share an insight, caveat, or question.
Tsuruoka et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: